Grapefruit Juice Inhibits the Metabolic Activation of Clopidogrel

被引:47
作者
Holmberg, M. T. [1 ,2 ]
Tornio, A. [1 ,2 ]
Neuvonen, M. [1 ,2 ]
Neuvonen, P. J. [1 ,2 ]
Backman, J. T. [1 ,2 ]
Niemi, M. [1 ,2 ]
机构
[1] Univ Helsinki, Dept Clin Pharmacol, SF-00250 Helsinki, Finland
[2] Univ Helsinki, Cent Hosp, HUSLAB, Helsinki, Finland
关键词
IMPLEMENTATION CONSORTIUM GUIDELINES; ACUTE CORONARY SYNDROMES; PLASMA-CONCENTRATIONS; CYP2C19; GENOTYPE; HEALTHY-SUBJECTS; MAJOR DETERMINANT; ORAL AVAILABILITY; GENETIC-VARIANTS; CYTOCHROMES P450; CITRUS JUICES;
D O I
10.1038/clpt.2013.192
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Cytochrome P450 (CYP) enzymes, including CYP2C19 and CYP3A4, participate in the bioactivation of clopidogrel. Grapefruit juice constituents potently inactivate intestinal CYP3A4 and have been shown to inhibit CYP2C19 as well. In a randomized crossover study, 14 healthy volunteers ingested 200 ml of grapefruit juice or water three times daily for 3 days. On day 3, they ingested a single 600-mg dose of clopidogrel. Grapefruit juice reduced the peak plasma concentration (C-max) of the active metabolite of clopidogrel to 13% of the control (range 11-17%, P < 0.001) and the area under the plasma concentration-time curve from 0 to 3 h to 14% (range 12-17%, P < 0.001) of the control, but it had no significant effect on the parent clopidogrel. Moreover, grapefruit juice markedly decreased the platelet-inhibitory effect of clopidogrel, as assessed with the VerifyNow P2Y12 test in two of the participants. In conclusion, concomitant use of grapefruit juice may impair the efficacy of clopidogrel. Therefore, the use of grapefruit juice is best avoided during clopidogrel therapy.
引用
收藏
页码:307 / 313
页数:7
相关论文
共 44 条
[1]
Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies [J].
Angiolillo, D. J. ;
Gibson, C. M. ;
Cheng, S. ;
Ollier, C. ;
Nicolas, O. ;
Bergougnan, L. ;
Perrin, L. ;
LaCreta, F. P. ;
Hurbin, F. ;
Dubar, M. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (01) :65-74
[2]
Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice [J].
Bailey, D. G. ;
Dresser, G. K. ;
Leake, B. F. ;
Kim, R. B. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (04) :495-502
[3]
Grapefruit-medication interactions: Forbidden fruit or avoidable consequences? [J].
Bailey, David G. ;
Dresser, George ;
Arnold, J. Malcolm O. .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2013, 185 (04) :309-316
[4]
Fruit juice inhibition of uptake transport: a new type of food-drug interaction [J].
Bailey, David G. .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (05) :645-655
[5]
INTERACTION OF CITRUS JUICES WITH FELODIPINE AND NIFEDIPINE [J].
BAILEY, DG ;
SPENCE, JD ;
MUNOZ, C ;
ARNOLD, JMO .
LANCET, 1991, 337 (8736) :268-269
[6]
Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients [J].
Bailey, DG ;
Dresser, GR ;
Kreeft, JH ;
Munoz, C ;
Freeman, DJ ;
Bend, JR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (05) :468-477
[7]
Paraoxonase-1 is a major determinant of clopidogrel efficacy [J].
Bouman, Heleen J. ;
Schoemig, Edgar ;
van Werkum, Jochem W. ;
Velder, Janna ;
Hackeng, Christian M. ;
Hirschhaeuser, Christoph ;
Waldmann, Christopher ;
Schmalz, Hans-Guenther ;
ten Berg, Jurrien M. ;
Taubert, Dirk .
NATURE MEDICINE, 2011, 17 (01) :110-U287
[8]
Cytochromes P450 Catalyze Both Steps of the Major Pathway of Clopidogrel Bioactivation, whereas Paraoxonase Catalyzes the Formation of a Minor Thiol Metabolite Isomer [J].
Dansette, Patrick M. ;
Rosi, Julien ;
Bertho, Gildas ;
Mansuy, Daniel .
CHEMICAL RESEARCH IN TOXICOLOGY, 2012, 25 (02) :348-356
[9]
Fruit Juices as Perpetrators of Drug Interactions: The Role of Organic Anion-Transporting Polypeptides [J].
Dolton, M. J. ;
Roufogalis, B. D. ;
McLachlan, A. J. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 92 (05) :622-630
[10]
Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine [J].
Dresser, GK ;
Bailey, DG ;
Leake, BF ;
Schwarz, UI ;
Dawson, PA ;
Freeman, DJ ;
Kim, RB .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (01) :11-20